Dual GIP/GLP-1 Receptor Agonist in Obese Women Before Frozen Embryo Transfer
ClinicalTrials.gov · NCT07811895 · Registry updated: 2026-09-10
- Condition / research focus
- Tirzepatide; Frozen Embryo Transfer; Obesity
- Sponsor
- RenJi Hospital
- Countries with listed sites
- China
- Registry dates and results
- Start: 2026-09. Completion: 2030-12 (may be estimated). No results posted in this registry response.
Products and interventions (1)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- Dual GIP/GLP-1 receptor agonist (drug) — also listed as: Tirzepatide
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- RenJi Hospital
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported